Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cullinan Therapeutics (CGEM) Non-Current Deffered Revenue (2020 - 2021)

Cullinan Therapeutics has reported Non-Current Deffered Revenue over the past 2 years, most recently at $65000.0 for Q4 2021.

  • Quarterly results put Non-Current Deffered Revenue at $65000.0 for Q4 2021, down 12.16% from a year ago — trailing twelve months through Dec 2021 was $65000.0 (down 12.16% YoY), and the annual figure for FY2021 was $65000.0, down 12.16%.
  • Non-Current Deffered Revenue for Q4 2021 was $65000.0 at Cullinan Therapeutics, down from $67000.0 in the prior quarter.
  • Over the last five years, Non-Current Deffered Revenue for CGEM hit a ceiling of $74000.0 in Q4 2020 and a floor of $65000.0 in Q4 2021.